PRESS RELEASE

Lund, November 20th, 2026

Hamlet BioPharma strengthens its board and business development expertise

Dr. Joel Silver will be proposed as a new board member at the annual general assembly held on November 20th 2026. His experience strengthens the company's medical and commercial expertise as it conducts the Phase III study of Alpha1H in bladder cancer and continues discussions with potential partners on further development and commercialisation.

"It means a great deal to us that Joel Silver and Tara Heitner have chosen to work with Hamlet BioPharma. With our Phase III study under way, we are also continuing discussions on the further development and commercialisation of Alpha1H and additional substances in our portfolio. Their experience of drug development, the US market and licensing will be very valuable at this stage," says Professor Catharina Svanborg, Chairman of the Board.

Dr. Silver has more than 50 years of experience in healthcare and pharmaceuticals. His previous positions include Associate Medical Director at Pfizer Laboratories, Director of the Medical Department at Revlon Health Care and Regional Medical Director at Oxford Research International Corporation. He is currently President of Silver and Company, advising on pharmaceutical development projects.

His work includes a pioneering role in the introduction of BCG to the US market and a longstanding involvement in bladder cancer, including clinical trials and interactions with the FDA. This experience will be particularly valuable to Hamlet BioPharma's continued development in the US.

In addition, the company welcomes and Dr. Tara Heitner as a business development advisor. Dr. Heitner brings extensive experience in drug development, licensing and commercialisation. She has led and signed pharmaceutical licensing agreements covering assets from early discovery to clinical development. As Head of Global Business Development at Ferring, she led late-stage business development and alliance management. Her work included FDA interactions, preparation for product launches and evaluation of new opportunities.

At Merck KGaA, she worked in scouting, evaluation and alliance management, mainly in oncology and immunology. Her experience includes raising capital from private investors and public markets and concluding licensing agreements with major pharmaceutical companies.

She holds a PhD in chemistry from McGill University, Canada, and an Executive MBA from the Technical University of Denmark.

The Board wishes to thank Professor Bill Hansson, for his important contributions to the company during his five years on the Board of Hamlet BioPharma. Professor Hansson will continue working with the drug development projects from a more scientific angle, in Linnane Pharma.

For further information, please contact:

Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49
catharina.svanborg@hamletpharma.com

Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10,
jakob.testad@hamletbiopharma.com

www.hamletbiopharma.com